-
公开(公告)号：US20110160157A1
公开(公告)日：2011-06-30
申请号：US12972908
申请日：2010-12-20
IPC分类号： A61K31/7056 , A61K31/404 , A61P1/00 , A61P25/28 , A61P29/00 , A61P19/02
CPC分类号： A61K31/404 , A61K31/7056
摘要： The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount less than sufficient to inhibit CDKs.
摘要翻译： 本发明涉及治疗与促炎细胞因子表达相关的炎性相关疾病和/或降低抗炎细胞因子表达的药物组合物和方法。 该方法通常包括一种或多种选自异靛，靛蓝，靛玉红或其衍生物的化合物，例如Meisoindigo和NATURA，其量小于足以抑制CDKs。
-
公开(公告)号：US20090325895A1
公开(公告)日：2009-12-31
申请号：US12548083
申请日：2009-08-26
IPC分类号： A61K31/7056 , A61K31/404
CPC分类号： A61K31/404 , A61K31/606 , A61K31/7056 , A61K45/00 , A61K45/06 , Y02A50/411 , A61K2300/00
摘要： The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.
摘要翻译： 本发明涉及治疗与促炎细胞因子表达相关的炎性相关疾病和/或降低抗炎细胞因子表达的药物组合物和方法。 该方法通常包括施用一种或多种选自异靛蓝，靛蓝，靛玉红或其衍生物的化合物，例如Meisoindigo和NATURA。 优选地，药物组合物包含一种或多种选自异靛蓝，靛蓝，靛玉红或其衍生物，抗炎剂和药学上可接受的载体的化合物。
-
公开(公告)号：US08563525B2
公开(公告)日：2013-10-22
申请号：US12972908
申请日：2010-12-20
CPC分类号： A61K31/404 , A61K31/7056
摘要： The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount less than sufficient to inhibit CDKs.
摘要翻译： 本发明涉及治疗与促炎细胞因子表达相关的炎性相关疾病和/或减少抗炎细胞因子表达的药物组合物和方法。 该方法通常包括一种或多种选自异靛，靛蓝，靛玉红或其衍生物的化合物，例如Meisoindigo和NATURA，其量小于足以抑制CDKs。
-
公开(公告)号：US08394847B2
公开(公告)日：2013-03-12
申请号：US12548083
申请日：2009-08-26
CPC分类号： A61K31/404 , A61K31/606 , A61K31/7056 , A61K45/00 , A61K45/06 , Y02A50/411 , A61K2300/00
摘要： The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.
-
公开(公告)号：US07582670B2
公开(公告)日：2009-09-01
申请号：US11104422
申请日：2005-04-13
IPC分类号： A61K31/40 , A61K31/404 , A61K31/56
CPC分类号： A61K31/404 , A61K31/606 , A61K31/7056 , A61K45/00 , A61K45/06 , Y02A50/411 , A61K2300/00
摘要： The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.
摘要翻译： 本发明涉及治疗与促炎细胞因子表达相关的炎性相关疾病和/或降低抗炎细胞因子表达的药物组合物和方法。 该方法通常包括施用一种或多种选自异靛蓝，靛蓝，靛玉红或其衍生物的化合物，例如Meisoindigo和NATURA。 优选地，药物组合物包含一种或多种选自异靛蓝，靛蓝，靛玉红或其衍生物，抗炎剂和药学上可接受的载体的化合物。
-
公开(公告)号：US20050154046A1
公开(公告)日：2005-07-14
申请号：US10754547
申请日：2004-01-12
申请人： Longgui Wang , Xiao Liu , Lian Mo , Simon Mencher , James McCarron
发明人： Longgui Wang , Xiao Liu , Lian Mo , Simon Mencher , James McCarron
IPC分类号： A61K31/404
CPC分类号： A61K31/404 , Y02A50/411 , Y02A50/463 , A61K2300/00
摘要： The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.
-
公开(公告)号：US20050197381A1
公开(公告)日：2005-09-08
申请号：US11104422
申请日：2005-04-13
申请人： Longgui Wang , Xiao Liu , Lian Mo , Simon Mencher , James McCarron
发明人： Longgui Wang , Xiao Liu , Lian Mo , Simon Mencher , James McCarron
IPC分类号： A61K31/404 , A61K31/7056 , A61K38/13
CPC分类号： A61K31/404 , A61K31/606 , A61K31/7056 , A61K45/00 , A61K45/06 , Y02A50/411 , A61K2300/00
摘要： The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier.
摘要翻译： 本发明涉及治疗与促炎细胞因子表达相关的炎性相关疾病和/或降低抗炎细胞因子表达的药物组合物和方法。 该方法通常包括施用一种或多种选自异靛蓝，靛蓝，靛玉红或其衍生物的化合物，例如Meisoindigo和NATURA。 优选地，药物组合物包含一种或多种选自异靛蓝，靛蓝，靛玉红或其衍生物，抗炎剂和药学上可接受的载体的化合物。
-
公开(公告)号：US20130261025A1
公开(公告)日：2013-10-03
申请号：US13565685
申请日：2012-08-02
申请人： Lauri Diehl , Kenneth Flanagan , Lian Mo
发明人： Lauri Diehl , Kenneth Flanagan , Lian Mo
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/158 , G01N33/6893
摘要： The present invention provides for a method of detecting the presence of inflammatory bowel disease in gastrointestinal tissues or cells of a mammal by detecting increased expression of LY6 genes in the tissues or cells of the mammal relative to a control.
-
公开(公告)号：US08257923B2
公开(公告)日：2012-09-04
申请号：US12984562
申请日：2011-01-04
申请人： Lauri Diehl , Kenneth Flanagan , Lian Mo
发明人： Lauri Diehl , Kenneth Flanagan , Lian Mo
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/158 , G01N33/6893
摘要： The present invention provides for a method of detecting the presence of inflammatory bowel disease in gastrointestinal tissues or cells of a mammal by detecting increased expression of LY6 genes in the tissues or cells of the mammal relative to a control.
摘要翻译： 本发明提供了一种通过检测哺乳动物组织或细胞中LY6基因相对于对照而增加的表达来检测胃肠组织或哺乳动物细胞中炎症性肠病的存在的方法。
-
公开(公告)号：US20110177504A1
公开(公告)日：2011-07-21
申请号：US12984562
申请日：2011-01-04
申请人： Lauri Diehl , Kenneth Flanagan , Lian Mo
发明人： Lauri Diehl , Kenneth Flanagan , Lian Mo
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/158 , G01N33/6893
摘要： The present invention provides for a method of detecting the presence of inflammatory bowel disease in gastrointestinal tissues or cells of a mammal by detecting increased expression of LY6 genes in the tissues or cells of the mammal relative to a control.
摘要翻译： 本发明提供了一种通过检测哺乳动物组织或细胞中LY6基因相对于对照而增加的表达来检测胃肠组织或哺乳动物细胞中炎症性肠病的存在的方法。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.042 秒)
